search
Back to results

Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model

Primary Purpose

Breast Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Nigeria
Study Type
Interventional
Intervention
iBreast device
Clinical Breast Examination
Breast ultrasound
Mammography
Sponsored by
Obafemi Awolowo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Breast Cancer focused on measuring Screening, Treatment, Navigation, Triple Mobile assessment

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Asymptomatic women 40 - 70 years
  • Symptomatic women (with breast-related symptoms) 30 - 70 years

Exclusion Criteria:

  • Male subjects
  • Women living outside the study locations (Ife East and Ife North districts)

Sites / Locations

  • Obafemi Awolowo University Teaching Hospitals ComplexRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

Intervention

Arm Description

Two districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. The control arm will not receive iBE screening and clinical breast examinations by the community health nurses and nor get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community. All women for screening and diagnostic workup in the control community will be directed to the tertiary hospital to receive breast care.

Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community. Women in the intervention community will receive iBreast and clinical breast examinations by the community health nurses and get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community.

Outcomes

Primary Outcome Measures

Participation rate
Percentage of women screened of the total number of eligible women in each community.
Abnormal call rate
Number of women with abnormalities detected on iBE and/or CBE requiring further evaluation either by imaging or biopsy out of the total number of women screened.
Breast cancer detection rate
Number of histologically diagnosed cases of breast cancer per 1,000 screened populations.
Stage at presentation
The tumour, node and metastasis (TNM) stage among those with histologically confirmed breast cancer.
Timeline from presentation to treatment
Time interval between presentation for screening in the community and treatment in the tertiary hospital
Retention rate
Number of women who return for repeat annual screening of the total initial number of women screened.

Secondary Outcome Measures

Full Information

First Posted
March 24, 2022
Last Updated
April 4, 2022
Sponsor
Obafemi Awolowo University
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT05321823
Brief Title
Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model
Official Title
Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 8, 2021 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Obafemi Awolowo University
Collaborators
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to establish a novel community-based breast cancer program to address delayed presentation and lack of access to diagnostic and treatment facilities in South-West Nigeria. It is aimed at evaluating the impact of a novel breast cancer early detection program using triple mobile assessment (innovative handheld iBreast Exam [iBE] device, mobile ultrasound, and mobile mammography) and patient navigation program in a Nigerian community.
Detailed Description
This study aims to provide screening to asymptomatic women 40-70 years and to provide diagnostic evaluation to women 30-70 years presenting with breast symptoms in a community in South-West Nigeria. The project will use a cluster randomized design with 1 community serving as the intervention arm and another community serving as the control arm. Both communities will receive breast cancer awareness and education but only the intervention community will receive screening, mobile imaging and navigation. Screening with targeted clinical history, Clinical Breast Exam (CBE), and iBE will be performed by trained Community Health Nurses in the intervention community. Women with positive CBE or iBE findings will undergo breast imaging with mobile mammography and portable ultrasound, as well as biopsy when indicated by the Radiologist who visits the community once a month, and receive navigation by the nurses to the point of care. The control population will receive breast cancer awareness without an organized screening, imaging or navigation program. Women presenting to the Primary Health Care Centers in the control community will be referred to the Teaching Hospital as per current standard of care. Record of all breast cancer cases seen in the 2 communities during the study period will be obtained.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Screening, Treatment, Navigation, Triple Mobile assessment

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study will be carried out in 2 local counties (Local Government Areas) in Osun State, South-West, Nigeria, Ife North Local County and Ife East Local County. Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community, while 2 districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. Both communities will receive awareness and education, but only the intervention community will receive screening and navigation.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Two districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. The control arm will not receive iBE screening and clinical breast examinations by the community health nurses and nor get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community. All women for screening and diagnostic workup in the control community will be directed to the tertiary hospital to receive breast care.
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community. Women in the intervention community will receive iBreast and clinical breast examinations by the community health nurses and get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community.
Intervention Type
Device
Intervention Name(s)
iBreast device
Other Intervention Name(s)
UE Life Sciences Inc.
Intervention Description
The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
Intervention Type
Other
Intervention Name(s)
Clinical Breast Examination
Other Intervention Name(s)
CBE
Intervention Description
The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
Intervention Type
Diagnostic Test
Intervention Name(s)
Breast ultrasound
Intervention Description
Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
Intervention Type
Diagnostic Test
Intervention Name(s)
Mammography
Intervention Description
Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
Primary Outcome Measure Information:
Title
Participation rate
Description
Percentage of women screened of the total number of eligible women in each community.
Time Frame
After year 1 of the 2-year study period
Title
Abnormal call rate
Description
Number of women with abnormalities detected on iBE and/or CBE requiring further evaluation either by imaging or biopsy out of the total number of women screened.
Time Frame
After year 1 of the 2-year study period
Title
Breast cancer detection rate
Description
Number of histologically diagnosed cases of breast cancer per 1,000 screened populations.
Time Frame
After year 1 of the 2-year study period
Title
Stage at presentation
Description
The tumour, node and metastasis (TNM) stage among those with histologically confirmed breast cancer.
Time Frame
After year 1 of the 2-year study period
Title
Timeline from presentation to treatment
Description
Time interval between presentation for screening in the community and treatment in the tertiary hospital
Time Frame
After year 1 of the 2-year study period
Title
Retention rate
Description
Number of women who return for repeat annual screening of the total initial number of women screened.
Time Frame
After year 2 of the 2-year study period

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
The study is addressing breast cancer screening and treatment in women
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Asymptomatic women 40 - 70 years Symptomatic women (with breast-related symptoms) 30 - 70 years Exclusion Criteria: Male subjects Women living outside the study locations (Ife East and Ife North districts)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adeleye D Omisore, MBBS, M.Sc, FWACS, FMCR
Phone
+234803538004
Email
leyeomisore@oauife.edu.ng
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adeleye D Omisore, MBBS, M.Sc, FWACS, FMCR
Organizational Affiliation
Obafemi Awolowo University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Obafemi Awolowo University Teaching Hospitals Complex
City
Ile Ife
State/Province
Osun
ZIP/Postal Code
220213
Country
Nigeria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adeleye D Omisore, MBBS, M.Sc, FWACS, FMCR
Phone
+2348031538004
Email
leyeomisore@oauife.edu.ng
First Name & Middle Initial & Last Name & Degree
Adeleye D Omisore, MBBS, M.Sc, FWACS, FMCR

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The study protocol, statistical analysis plan, and informed consent form will be made available on clinicaltrials.gov if and when required. With study data being uploaded to redcap hosted by the sponsor organization (Obafemi Awolowo University), de-identified individual participant data can be made available under the terms of a data use agreement 12 moths after publication of study results.
IPD Sharing Time Frame
The data can be available beginning 12 months after publication of the study results up to to 36 months post publication.
IPD Sharing Access Criteria
Researchers with approved proposals

Learn more about this trial

Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model

We'll reach out to this number within 24 hrs